Elisabet Domínguez-Clavé

Chemotherapy-induced peripheral neuropathy is a side effect of platinum-based cancer treatments that affects more than 60 per cent of patients and causes pain, a burning sensation and numbness. The psychedelic compound psilocybin could help prevent it, according to researchers behind a study using mouse models published in Science. Two doses of psilocybin administered prior to treatment prevented peripheral neuropathy for up to six cycles of chemotherapy without reducing its anti-tumour effects. The author of another perspective article on this study, also in Science, states that “the challenge now is to translate this understanding of the underlying mechanisms into carefully designed clinical trials”.

In 2023, 1.17 billion people suffered from a mental health disorder, compared to 599 million people in 1990, according to a global study published in The Lancet. Women experienced higher rates of anxiety and depression, while neurodevelopmental and behavioral disorders—such as ADHD or autism—are more common in men. The highest incidence was observed among those aged 15 to 19, which, according to the authors, underscores the need for early prevention and targeted support for this age group.

Single and repeated intravenous ketamine infusions are effective in reducing suicidal and depressive symptoms in patients with an acute episode of major depression. These are the main conclusions of a systematic review and meta-analysis published today in the journal JAMA Psychiatry, which also notes that long-term outcomes are not well established.

The hallucinogen psilocybin, found in certain mushrooms, is being investigated as a treatment for conditions such as depression. A study published in Nature Communications shows that a single 25 mg dose of the compound can produce brain changes lasting up to a month after administration. These were measured using neuroimaging techniques in 28 healthy adults who had never taken psychedelics. In terms of psychological effects, participants showed increased cognitive flexibility, psychological insight, and well-being after one month.

The study of psychedelic drugs in pharmacological treatments had its eureka moment with chemist Albert Hofmann's famous bike ride under the influence of LSD in 1938 and then developed over decades, but with Richard Nixon it was shelved. In recent years, it has resurfaced in hospitals and laboratories around the world. Last week, the Congress of Deputies hosted a conference on these substances. We explain what they are, what they are used for, the current state of research, and their risks, with the help of expert sources.

Dimethyltryptamine (DMT) is responsible for the psychedelic effects of ayahuasca. According to the results of a phase IIa clinical trial published in Nature Medicine, this molecule improved depressive symptoms in adults with depression after one dose. The trial included 34 people, 17 of whom received intravenous DMT. This second group showed greater improvements in depressive symptoms than the control group. After two weeks, in the second part of the trial, DMT was administered to all participants and the antidepressant effects lasted for three months. Adverse effects were mainly pain at the injection site, nausea and transient anxiety.

The American Psychiatric Association has unveiled the new features of the forthcoming Diagnostic and Statistical Manual of Mental Disorders (DSM) in five articles published in The American Journal of Psychiatry. Among the highlights are the proposed change of name — it will become the Diagnostic and Scientific Manual — and the intention for it to be more dynamic, incorporating biomarkers for diagnosis and integrating the socioeconomic, cultural and environmental determinants of health. According to the authors, the aim is to enable a more personalised and inclusive clinical practice, aligned with scientific rigour. The most recent update was published in 2022 with the DSM-5-TR, and specialists are currently unaware of the date of the next edition, as they reported during a briefing with journalists.

According to a study published in the journal JAMA Health Forum, the use of the benzodiazepine lorazepam by the character Victoria Ratliff in the series The White Lotus was associated in the United States with an increase in Google searches for this medication, including queries about how to obtain it online. The series generated 1.6 million more searches than usual over a 12-week period. Although the study reflects searches for information and not actual consumption, the abuse of anti-anxiety drugs is a fact: illegal sales of benzodiazepines have increased in the United States, and Spain leads the rankings in terms of consumption.